Susquehanna International Group’s Argos Therapeutics, Inc. ARGS Stock Holding History

Susquehanna International Group’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-665	Closed	-$6K	–	10470
2017 Q1	$6K	Sell	665 -225	-25%	-$14.2K	﹤0.01%	8795
2016 Q4	$87K	Buy	+890	New	+$83.3K	﹤0.01%	9141
2016 Q3	–	Sell	-1,605	Closed	-$197K	–	9717
2016 Q2	$197K	Buy	+1,605	New	+$214K	﹤0.01%	7624

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Susquehanna International Group's ARGS Position: Q2 2018 in Review

Susquehanna International Group sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2018, closing a stake of 10,724 shares — an estimated $10K sold.

Susquehanna International Group first reported a position in ARGS in Q4 2016 and held it in 4 quarters. The position peaked at $5.02M in Q4 2016. 4 funds tracked by Wall St. Rank hold ARGS as of Q2 2018.

Susquehanna International Group reported no remaining Argos Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Susquehanna International Group sold 10,724 Argos Therapeutics, Inc. shares in Q2 2018, an estimated $10K.
Susquehanna International Group first reported a position in Argos Therapeutics, Inc. in Q4 2016 and held it in 4 quarters.
Susquehanna International Group's Argos Therapeutics, Inc. position peaked at $5.02M in Q4 2016.
4 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2018.

Based on Susquehanna International Group's 13F filing for Q2 2018, filed 14 Aug 2018.